Literature DB >> 31089924

Sporadic and Von-Hippel Lindau disease-associated spinal hemangioblastomas: institutional experience on their similarities and differences.

Andrew Yousef1, Martin J Rutkowski2, Can Ege Yalcin3, Ozgur Can Eren3, Ilay Caliskan3, Tarik Tihan3.   

Abstract

INTRODUCTION: Hemangioblastomas are uncommon tumors of the central nervous system that can be seen in Von Hippel-Lindau (VHL) disease. Despite their benign histology, hemangioblastomas can cause substantial morbidity due to involvement of critical structures. In order to better understand the clinical behavior of spinal cord hemangioblastomas, we have analyzed the clinical, pathologic, radiologic characteristics and management of sporadic and VHL-associated cases at our institution.
METHODS: We performed a database search to identify all spinal hemangioblastomas at our institution between 1997 and 2016. Tumor characteristics were analyzed for sporadic and VHL-associated tumors separately in order to understand the differences in groups.
RESULTS: We included 20 patients with VHL-associated spinal hemangioblastomas, and 22 patients with sporadic spinal hemangioblastomas. VHL-associated patients were significantly younger at time of presentation compared to sporadic patients (p < 0.0025). Thirty-two patients (76.2%) presented with focal weakness, 34 (81.0%) with sensory loss, and 22 (52.4%) with pain. VHL patients were more likely to present with multiple symptoms (p < 0.001). Median follow-up time was 20.9 months, during which 17 tumors recurred. The median recurrence free interval was 44 months. There were no differences in gross total resection rates between sporadic and VHL-associated cases (p = 0.197). VHL-associated cases had a higher rate of repeat surgery for recurrence (14 patients-73.6%) compared to sporadic cases (3 patients-13.6%; p < 0.001).
CONCLUSION: VHL-associated spinal hemangioblastomas differ from sporadic tumors in terms of age, presenting symptoms, multifocality, and rate of recurrence. Recurrences seem to be unrelated to the extent of resection, indicating the need for life-long follow up for VHL patients.

Entities:  

Keywords:  Hemangioblastoma; Neuro-Oncology; Spinal hemangioblastoma; Spine; Von Hippel-Lindau

Mesh:

Year:  2019        PMID: 31089924     DOI: 10.1007/s11060-019-03189-w

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  4 in total

1.  Spinal hemangioblastomas: analysis of surgical outcome and prognostic factors.

Authors:  Alberto Feletti; Alessandro Boaro; Davide Giampiccolo; Giorgio Casoli; Fabio Moscolo; Massimiliano Ferrara; Francesco Sala; Giacomo Pavesi
Journal:  Neurosurg Rev       Date:  2021-11-25       Impact factor: 3.042

Review 2.  Sporadic hemangioblastoma of cauda equina: A case report and brief literature review.

Authors:  Salvatore D' Oria; David Giraldi; Daniel Andres Alvarado Flores; Domenico Murrone; Vincenzo D' Angelo; Bipin Chaurasia
Journal:  J Craniovertebr Junction Spine       Date:  2022-09-14

3.  Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database.

Authors:  Xiangdong Yin; Hongzhou Duan; Zhiqiang Yi; Chunwei Li; Runchun Lu; Liang Li
Journal:  Front Oncol       Date:  2020-09-09       Impact factor: 6.244

Review 4.  Neuropathologic features of central nervous system hemangioblastoma.

Authors:  Rebecca A Yoda; Patrick J Cimino
Journal:  J Pathol Transl Med       Date:  2022-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.